Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Erik Kristensen

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
The Journal of Rheumatology|November 2, 2021
Is Real-world Evidence Really Real?Lars Erik Kristensen, Alexander Egeberg
Annals of the Rheumatic Diseases|August 3, 2017
Impact of age and sex on the incidence and prevalence of psoriatic arthritisAlexander Egeberg, Lars Erik Kristensen
Ugeskrift for Laeger|November 26, 2003
[Severe hypothermia]Lars Erik Kristensen, Finn Larssen-Aas
Arthritis and Rheumatism|February 1, 2006
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern SwedenLars Erik Kristensen, Tore Saxne, Pierre Geborek
The Journal of Rheumatology|February 12, 2009
Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern SwedenAnders Gülfe, Lars Erik Kristensen, Pierre Geborek
The American Journal of Gastroenterology|January 5, 2022
Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to TofacitinibCasper Steenholdt, Lars Erik Kristensen, Jørn Brynskov
Arthritis Research & Therapy|February 20, 2016
EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern SwedenAnders Gülfe, Johan K Wallman, Lars Erik Kristensen
International Journal of Chronic Obstructive Pulmonary Disease|October 8, 2016
Increased mortality in patients with severe COPD associated with high-intensity exercise: a preliminary cohort studyLone Schaadt, Robin Christensen, Lars Erik Kristensen, et al.
Autoimmunity Reviews|September 15, 2018
Nutritional recommendations for gout: An update from clinical epidemiologySabrina Mai Nielsen, Kristian Zobbe, Lars Erik Kristensen, et al.
Arthritis Research & Therapy|November 24, 2006
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenLars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, et al.
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
The Journal of Rheumatology|November 2, 2021
Is Real-world Evidence Really Real?Lars Erik Kristensen, Alexander Egeberg
Annals of the Rheumatic Diseases|August 3, 2017
Impact of age and sex on the incidence and prevalence of psoriatic arthritisAlexander Egeberg, Lars Erik Kristensen
Ugeskrift for Laeger|November 26, 2003
[Severe hypothermia]Lars Erik Kristensen, Finn Larssen-Aas
Arthritis and Rheumatism|February 1, 2006
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern SwedenLars Erik Kristensen, Tore Saxne, Pierre Geborek
The Journal of Rheumatology|February 12, 2009
Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern SwedenAnders Gülfe, Lars Erik Kristensen, Pierre Geborek
The American Journal of Gastroenterology|January 5, 2022
Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to TofacitinibCasper Steenholdt, Lars Erik Kristensen, Jørn Brynskov
Arthritis Research & Therapy|February 20, 2016
EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern SwedenAnders Gülfe, Johan K Wallman, Lars Erik Kristensen
International Journal of Chronic Obstructive Pulmonary Disease|October 8, 2016
Increased mortality in patients with severe COPD associated with high-intensity exercise: a preliminary cohort studyLone Schaadt, Robin Christensen, Lars Erik Kristensen, et al.
Autoimmunity Reviews|September 15, 2018
Nutritional recommendations for gout: An update from clinical epidemiologySabrina Mai Nielsen, Kristian Zobbe, Lars Erik Kristensen, et al.
Arthritis Research & Therapy|November 24, 2006
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenLars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, et al.
Pageof 14